MLPA® Kits

For a description how to create and adapt MLPA Kits, that are not available on this page, please have a look at our User Manual MLPA.

Import of SALSA MLPA® kit descriptions via the SEQUENCE Pilot operation "Mixes [master file] / button [Import]".

Mix
Version
Date
Region
Application
Vs. 08
09-10-2011
LEPR, POMC, LEP, SIM1, MC3R, MC4R Obesity
P220-B1 Vs. 09 20-12-2011 LEPR, POMC, LEP, SIM1, MC3R, MC4R Obesity
P220-B1 Vs. 10 21-12-2012 LEPR, POMC, LEP, SIM1, MC3R, MC4R Obesity
P220-B1 Vs. 11 22-06-2015 LEPR, POMC, LEP, SIM1, MC3R, MC4R Obesity
P220-B1 Vs. 13 09-03-2016 LEPR, POMC, LEP, SIM1, MC3R, MC4R Obesity
Vs. 03
02-07-2008
AIPL1 17p13, CRB1 1q31, CRX 19q13, RPE65 1p31 Leber congenital amaurosis (LCA)
Vs. 05
02-07-2012
AIPL1 17p13, CRB1 1q31, CRX 19q13, RPE65 1p31 Leber congenital amaurosis (LCA)
P221-B1 Vs. 07 12-03-2013 AIPL1 17p13, CRB1 1q31, CRX 19q13, RPE65 1p31 Leber congenital amaurosis (LCA)
P221-B1 Vs. 08 24-11-2014 AIPL1 17p13, CRB1 1q31, CRX 19q13, RPE65 1p31 Leber congenital amaurosis (LCA)
P221-C1 Vs. 10 19-05-2015 AIPL1 17p13, CRB1 1q31, CRX 19q13, RPE65 1p31 Leber congenital amaurosis (LCA)
P221-C1 Vs. 11 18-08-2016 AIPL1 17p13, CRB1 1q31, CRX 19q13, RPE65 1p31 Leber congenital amaurosis (LCA)
Vs. 07
01-10-2011
GUCY2D 17p13.1, RDH12 14q24, RPGRIP1 14q11, CEP290 12q21 Leber congenital amaurosis (LCA)
P222-A2 Vs. 10 01-03-2013 GUCY2D 17p13.1, RDH12 14q24, RPGRIP1 14q11, CEP290 12q2 Leber congenital amaurosis (LCA)
P222-A2 Vs. 11 17-07-2015 GUCY2D 17p13.1, RDH12 14q24, RPGRIP1 14q11, CEP290 12q2 Leber congenital amaurosis (LCA)
P222-B1 Vs. 12 11-03-2016 GUCY2D 17p13.1, RDH12 14q24, RPGRIP1 14q11, CEP290 12q2 Leber congenital amaurosis (LCA)
Vs. 05
16-11-2010
PHEX Xp22.2, FGF23 12p13 Hypophosphatemia, x-linked
Vs. 06
01-10-2011
PHEX Xp22.2, FGF23 12p13 Hypophosphatemia, x-linked
Vs. 07
16-12-2012
PHEX Xp22.2, FGF23 12p13 Hypophosphatemia, x-linked
Vs. 08
22-11-2013
PHEX Xp22.2, FGF23 12p13 Hypophosphatemia, x-linked
Vs. 09
09-05-2016
PHEX Xp22.2, FGF23 12p13 Hypophosphatemia, x-linked
Vs. 08
21-12-2012
PPARG 3p25.1 Obesity, Diabetes mellitis type II, Familial partial lipodystrophy III, Colon cancer
P225-C1 Vs. 15 01-03-2013 PTEN 10q23 Cancer
P225-D1 Vs. 16 20-11-2013 PTEN 10q23 Cancer
P225-D2 Vs. 17 29-05-2015 PTEN 10q23 Cancer
P225-D2 Vs. 19 17-06-2016 PTEN 10q23 Cancer
P225-D2 Vs. 21 21-03-2017 PTEN 10q23 Cancer
P225-D2 Vs. 22 07-09-2017 PTEN 10q23 Cancer
Vs. 12
13-12-2011
SDHD 11q23.1, SDHB 1p36.1, SDHC 1q23.3 Paragangliomas (PGL)
P226-C1 Vs. 13 07-09-2012 SDHD 11q23.1, SDHB 1p36.1, SDHC 1q23.3 Paragangliomas (PGL)
P226-C1 Vs. 15 04-01-2013 SDHD 11q23.1, SDHB 1p36.1, SDHC 1q23.3 Paragangliomas (PGL)
P226-C1 Vs. 16 17-07-2015 SDHD 11q23.1, SDHB 1p36.1, SDHC 1q23.3 Paragangliomas (PGL)
P226-C1 Vs. 18 29-02-2016 SDHD 11q23.1, SDHB 1p36.1, SDHC 1q23.3 Paragangliomas (PGL)
Vs. 04
09-11-2010
SerpinC1 1q25.1 Antithrombin (III) deficiency
Vs. 06
01-10-2011
SerpinC1 1q25.1 Antithrombin (III) deficiency
P227-B1 Vs. 07 14-09-2012 SerpinC1 1q25.1 Antithrombin (III) deficiency
P227-B1 Vs. 08 21-12-2012 SerpinC1 1q25.1 Antithrombin (III) deficiency
P227-B2 Vs. 09 13-03-2014 SerpinC1 1q25.1 Antithrombin (III) deficiency
P227-B3 Vs. 10 05-10-2017 SerpinC1 1q25.1 Antithrombin (III) deficiency
Vs. 01
07-07-2007
TRPS1 8q24 Trichorhinophalangeal syndrome type I (TRPS1), Langer-Giedion syndrome (LGS)
Vs. 05
24-08-2011
TRPS1 8q24 Trichorhinophalangeal syndrome type I (TRPS1), Langer-Giedion syndrome (LGS)
Vs. 08
10-07-2014
TRPS1 8q24 Trichorhinophalangeal syndrome type I (TRPS1), Langer-Giedion syndrome (LGS)
Vs. 09
11-10-2017
TRPS1 8q24 Trichorhinophalangeal syndrome type I (TRPS1), Langer-Giedion syndrome (LGS)
Vs. 11
01-10-2011
OPA1 3q28, VMD2 11q13, RDS 6p21.2 Macular dystrophy
P229-B2 Vs. 12 14-07-2012 OPA1 3q28, VMD2 11q13, RDS 6p21.2 Macular dystrophy
P229-B2 Vs. 13 21-12-2012 OPA1 3q28, VMD2 11q13, RDS 6p21.2 Macular dystrophy
P229-B2 Vs. 14 21-01-2015 OPA1 3q28, VMD2 11q13, RDS 6p21.2 Macular dystrophy
P229-B3 Vs. 15 15-04-2015 OPA1 3q28, VMD2 11q13, RDS 6p21.2 Macular dystrophy
Vs. 05
29-01-2009
9p, 10p, 11p, 12p Subtelomeric screening
Vs. 10
09-10-2011
9p, 10p, 11p, 12p Subtelomeric screening
Vs. 12
24-06-2015
9p, 10p, 11p, 12p Subtelomeric screening
Vs. 14
02-03-2018
9p, 10p, 11p, 12p Subtelomeric screening
Vs. 04
16-03-2011
FGF10 5p13, FGFR2 10q26 Autosomal dominant lacrimoauriculodentodigital (LADD)
Vs. 07
16-10-2013
FGF10 5p13, FGFR2 10q26 Autosomal dominant lacrimoauriculodentodigital (LADD)
Vs. 08
21-10-2016
FGF10 5p13, FGFR2 10q26 Autosomal dominant lacrimoauriculodentodigital (LADD)
Vs. 03
29-07-2009
FGD1 Xp11.21 Faciogenital dysplasia (FGDY), Aarskog-Scott syndrome
Vs. 05
09-10-2011
FGD1 Xp11.21 Faciogenital dysplasia (FGDY), Aarskog-Scott syndrome
P232-C1 Vs. 07 16-12-2012 FGD1 Xp11.21 Faciogenital dysplasia (FGDY), Aarskog-Scott syndrome
Vs. 05
24-08-2011
MID1 Xp22 OPITZ syndrome
Vs. 06 16-12-2012 MID1 Xp22 OPITZ syndrome
P233-B2 Vs. 07 10-09-2013 MID1 Xp22 OPITZ syndrome
Vs. 04
02-10-2008
GATA4 8p23, GATA3 10p15 Cardiac septal defects
Vs. 06
24-08-2011
GATA4 8p23, GATA3 10p15 Cardiac septal defects
Vs. 09
26-03-2013
GATA4 8p23, GATA3 10p15 Cardiac septal defects
Vs. 11
19-09-2016
GATA4 8p23, GATA3 10p15 Cardiac septal defects
Vs. 02
11-01-2010
RHO 3q21.3, RP1 8q11.2, IMPDH1 7q32, PRPF31 19q13.4 Retinitis Pigmentosa
Vs. 03
24-08-2010
RHO 3q21.3, RP1 8q11.2, IMPDH1 7q32, PRPF31 19q13.4 Retinitis Pigmentosa
Vs. 05
30-01-2014
RHO 3q21.3, RP1 8q11.2, IMPDH1 7q32, PRPF31 19q13.4 Retinitis Pigmentosa
Vs. 06
17-06-2017
RHO 3q21.3, RP1 8q11.2, IMPDH1 7q32, PRPF31 19q13.4 Retinitis Pigmentosa
Vs. 09
24-08-2011
CFH, CFHR3, CFHR1, CFHR2, 1q23 Age-related macular degeneration (ARMD)
P236-A3 Vs. 10 19-09-2011 CFH, CFHR3, CFHR1, CFHR2, 1q23 Age-related macular degeneration (ARMD)
P236-A3 Vs. 11 16-12-2012 CFH, CFHR3, CFHR1, CFHR2, 1q23 Age-related macular degeneration (ARMD)
P236-A3 Vs. 12 13-05-2013 CFH, CFHR3, CFHR1, CFHR2, 1q23 Age-related macular degeneration (ARMD)
P236-A3 Vs. 13 17-07-2015 CFH, CFHR3, CFHR1, CFHR2, 1q23 Age-related macular degeneration (ARMD)
P236-A3 Vs. 14 08-03-2016 CFH, CFHR3, CFHR1, CFHR2, 1q23 Age-related macular degeneration (ARMD)
P236-A3 Vs. 15 12-07-2016 CFH, CFHR3, CFHR1, CFHR2, 1q23 Age-related macular degeneration (ARMD)
Vs. 03
26-08-2011
DNAI1 9p21 Primary ciliary dyskinesia (PCD)
Vs. 06
26-02-2013
DNAI1 9p21 Primary ciliary dyskinesia (PCD)
Vs. 02
23-05-2008
DNAH5 5p15 Primary ciliary dyskinesia (PCD)
Vs. 07
08-02-2013
DNAH5 5p15 Primary ciliary dyskinesia (PCD)
Vs. 09
14-06-2016
DNAH5 5p15 Primary ciliary dyskinesia (PCD)
Vs. 06
30-07-2009
BRCA1 region Breast cancer
Vs. 09
17-12-2012
BRCA1 region Breast cancer